证券代码：688120 证券简称：华海清科 公告编号：2025-006 华海清科股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司应在每个月的前 3 个交易日内公告截至上月 末的回购进展情况。现将公司回购股份进展的具体情况公告如下： | 回购方案首次披露日 | 2024/3/5，由董事长路新春先生提议 | | --- | --- | | 回购方案实施期限 | 待股东大会审议通过后 12 个月 | | 预计回购金额 | 5,000 万元~10,000 万元 | | 回购用途 | 用于员工持股计划或股权激励、用于转换公司可转债 | | 累计已回购股数 | 513,031 股 | | 累计已回购股数占总股本比例 | 0.22% | | 累计已回购金额 | 7,991.92 万元 | | 实际回购价格区间 | 124.59 元/股~179.00 元/股 | 注：1、因华海清科股份有限公司（以下简称"公司"）实施 2023 年年度权益 分派事项，本次以集中竞价交易方式回购股份价格上限由不超过 260.00 ...

国泰君安证券股份有限公司关于 华海清科股份有限公司核心技术人员调整的核查意见 赵德文任职期间参与了部分研发项目和知识产权研发工作，其任职期间参与 研究并申请的专利均为职务成果，截至本核查意见出具之日，该等职务成果所形 成的知识产权之所有权均归属于公司，不存在涉及职务成果、知识产权相关的纠 纷或潜在纠纷，本次调整核心技术人员不会影响公司专利权等知识产权的完整性。 （三）保密协议情况 华海清科与赵德文签署的《劳动合同》对知识产权、保密义务以及相关权利 义务等进行了明确的约定。赵德文对其知悉、接触、了解的公司商业秘密及其他 需要保密的信息负有严格的保密义务。截至本公告披露日，华海清科未发现赵德 文有违反上述义务的情形。本次调整后，赵德文将担任公司高级顾问，将继续遵 守上述关于知识产权、保密、竞业限制等义务。 一、核心技术人员调整的具体情况 华海清科高级管理人员暨核心技术人员赵德文先生近日因个人原因，申请辞 去副总经理职务，辞职报告自送达公司董事会之日起生效。赵德文辞职后将担任 公司高级顾问，不再涉及核心研发工作，因此公司不再认定赵德文为核心技术人 员。 （一）核心技术人员具体情况 赵德文，男，1984 年生，中国国 ...

证券代码：688120 证券简称：华海清科 公告编号：2025-005 华海清科股份有限公司 关于公司高级管理人员暨核心技术人员调整的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 华海清科股份有限公司（以下简称"公司"）副总经理赵德文先生因个人原 因辞去副总经理职务，不再涉及核心研发工作，因此不再认定赵德文先生为核心 技术人员；同时为进一步完善公司治理结构，聘任王科先生为公司副总经理。 公司一直重视自主知识产权的研发，已建立完善的研发管理体系和知识产权 保护体系。本次调整核心技术人员不会影响公司拥有的核心技术及其专利权属完 整性，亦不会对公司的核心竞争力、技术优势、业务及产品创新能力产生重大不 利影响。 一、公司高级管理人员调整的具体情况 公司董事会近日收到副总经理赵德文先生的辞职报告，赵德文先生因个人原 因辞去副总经理职务，辞职报告自送达公司董事会之日起生效。赵德文先生辞职 后将担任公司高级顾问，不再涉及核心研发工作，因此公司不再认定赵德文先生 为核心技术人员。上述人员的上述调整不会对公司的正常运 ...

证券代码：688120 证券简称：华海清科 公告编号：2025-004 华海清科股份有限公司 2024 年年度业绩预增的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1、华海清科股份有限公司（以下简称"公司"）预计 2024 年年度实现营业 收入为 335,000.00 万元至 375,000.00 万元，较上年同期相比增加 84,200.89 万 元至 124,200.89 万元，同比增长 33.57%至 49.52%。 2、公司预计 2024 年年度实现归属于母公司所有者的净利润为 97,000.00 万 元至 108,000.00 万元，较上年同期相比增加 24,625.34 万元至 35,625.34 万元， 同比增长 34.02%至 49.22%。 3、公司预计 2024 年年度实现归属于母公司所有者的扣除非经常性损益的净 利润为 82,000.00 万元至 91,000.00 万元，较上年同期相比增加 21,187.89 万元 至 30,187.89 万元，同比增长 34.84 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 华海清科股份有限公司（以下简称"公司"）于 2024 年 11 月 30 日披露了 《华海清科股份有限公司关于公司间接控股股东四川省能源投资集团有限责任 公司筹划战略重组的提示性公告》（公告编号：2024-064），四川省人民政府拟 启动公司间接控股股东四川省能源投资集团有限责任公司（以下简称"能投集团"） 与四川省投资集团有限责任公司（以下简称"川投集团"）的战略重组事宜。 2024 年 12 月 30 日，公司收到能投集团通知，获悉能投集团与川投集团于 当日签署了《四川省投资集团有限责任公司与四川省能源投资集团有限责任公司 之合并协议》。根据该协议，能投集团与川投集团实施新设合并（以下简称"本 次合并"）。新设公司名称为"四川能源发展集团有限责任公司"（以下简称"四 川能源发展集团"，最终以公司登记为准）。四川能源发展集团股东分别为四川 省政府国有资产监督管理委员会、四川发展（控股）有限责任公司及四川省财政 厅，实际控制人为四川省政府国有资产监督管理委员会。合并前能投集团 ...

国泰君安证券股份有限公司 关于华海清科股份有限公司 2024 年度持续督导工作现场检查报告 国泰君安证券股份有限公司（以下简称"国泰君安"或"保荐机构"）作为 华海清科股份有限公司（以下简称"华海清科"或"公司"）首次公开发行股票 并在科创板上市的保荐机构及持续督导机构，根据《上海证券交易所科创板股票 上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 等相关法律法规的规定，对公司 2024 年 1 月 1 日至本次现场检查日期（以下简 称"本持续督导期间"）的规范运作情况进行了现场检查，现就现场检查的有关 情况报告如下： 一、 本次现场检查的基本情况 （一）保荐机构及保荐代表人 国泰君安证券股份有限公司：陈圳寅、裴文斐 （二）现场检查时间 2024 年 12 月 24 日至 25 日 （三）现场检查人员 陈圳寅 （四）现场检查内容 公司治理和内部控制情况、信息披露情况、独立性情况、与控股股东、实际 控制人及其他关联方资金往来情况、募集资金使用情况、关联交易、对外担保、 重大对外投资、公司经营情况等。 （五）现场检查手段 查看公司主要生产经营场所并与公司董事会秘书、财务负责人访谈；查 ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative performance of over 15% compared to the benchmark in the next six months [9][15]. Core Insights - The company is set to benefit from the rapid development in AI and high-performance computing, leading to increased demand for its CMP and thinning equipment, which are critical for advanced packaging technologies [2]. - The acquisition of the remaining 82% stake in the subsidiary, Chiplet, is structured with a performance-based compensation mechanism to mitigate acquisition risks and incentivize the core technical team [9][21]. - The company's projected net profits for 2024-2026 are 10.9 billion, 13.8 billion, and 15.8 billion CNY, with corresponding dynamic P/E ratios of 40, 31, and 27 [22]. Financial Summary - The company’s operating cash flow is expected to increase from 653 million CNY in 2023 to 1,153 million CNY in 2024, with a projected net profit margin of 30.78% in 2024 [6][28]. - Revenue is forecasted to grow from 2.51 billion CNY in 2023 to 3.53 billion CNY in 2024, reflecting a year-on-year growth rate of 40.92% [28]. - The company’s total assets are projected to rise from 9.12 billion CNY in 2023 to 11.99 billion CNY in 2024, indicating a strong growth trajectory [33].

Investment Rating - Maintains an "Overweight" rating with a target price of 172.47 yuan, corresponding to a PE ratio of 40, 31, and 24 times for 2024, 2025, and 2026 respectively [3][29] Core Views - The company is consolidating its competitive advantage in CMP while expanding its product line, with significant progress in thinning, cleaning, and measurement equipment [2] - The acquisition of Xinyu Semiconductor, which specializes in ion implantation machines, aligns with the company's "equipment + service" platform strategy and is expected to become a new growth curve [25][26][30] - The ion implantation market is highly monopolized by US companies, with a domestic substitution rate of less than 10%, presenting a significant opportunity for the company [27][31] Financial Projections - Revenue forecasts for 2024-2026 are 3.50, 4.74, and 6.034 billion yuan, representing year-on-year growth of 40%, 35%, and 27% respectively [3] - Net profit attributable to the parent company for 2024-2026 is projected to be 1.009, 1.336, and 1.702 billion yuan, with year-on-year growth of 39%, 32%, and 27% respectively [3] - EPS for 2024-2026 is expected to be 4.26, 5.64, and 7.19 yuan [3] Product Line Progress - Thinning equipment: The 12-inch ultra-precision wafer thinning machine Versatile-GP300 has received bulk orders from leading companies, and the Versatile-GM300 has been sent to a leading domestic packaging and testing company for verification [2] - Cutting equipment: The 12-inch wafer edge cutting equipment has been sent to multiple customers for verification [2] - Cleaning equipment: Batch production has been achieved for wafer regeneration, and brush cleaning equipment for 4/6/8-inch compound semiconductors has passed customer acceptance [2] - Thickness measurement equipment: Small batch shipments have been achieved for metal process thickness measurement, with repeat orders from a leading integrated circuit manufacturer [2] Acquisition Details - The company plans to acquire the remaining 82% stake in Xinyu Semiconductor for up to 1 billion yuan, valuing the subsidiary at 1.225 billion yuan [25] - The acquisition includes performance commitments for 2024-2026, with revenue targets of 0.45, 1.05, and 3.4 billion yuan, and delivery targets of 4 and 8 units for 2024 and 2025 respectively [26] - A comprehensive excess reward mechanism is in place, with potential rewards of 10-20 million yuan for 2025 and 20-30 million yuan for 2026 based on performance [27] Industry Context - The ion implantation market is expected to reach 11 billion yuan by 2025, with low/medium/high energy implantation machines accounting for 61%, 20%, and 18% respectively [27] - The domestic substitution rate for ion implantation equipment is less than 10%, with US companies dominating the market, making it a critical area for domestic substitution [27][31]

Investment Rating - The report assigns a "BUY" rating for Huahai Qingke (688120.SH) with a target price of 220 CNY [1][7]. Core Insights - The company is expected to see significant growth in net profit from 2024 to 2026, with projections of 9.6 billion CNY, 12.7 billion CNY, and 15.7 billion CNY, representing year-on-year growth rates of 33%, 32%, and 24% respectively [7][8]. - The acquisition of the remaining 82% stake in subsidiary Xinyu Semiconductor for 1 billion CNY is aimed at deepening the company's presence in the ion implantation equipment sector, which is expected to enhance its product matrix and long-term growth potential [8]. - The company reported record high revenues and net profits in Q3 2024, achieving 2.9 billion CNY in net profit, a year-on-year increase of 51.7% [8]. Financial Summary - The company’s revenue is projected to grow from 25.08 billion CNY in 2023 to 35.04 billion CNY in 2024, with a corresponding increase in operating profit from 790 million CNY to 1.038 billion CNY [11]. - The earnings per share (EPS) are forecasted to rise from 4.05 CNY in 2024 to 6.64 CNY in 2026, with the price-to-earnings (P/E) ratio decreasing from 42 times in 2024 to 26 times in 2026 [7][22]. - The cash flow from operating activities is expected to increase significantly, reaching 1.123 billion CNY in 2024, compared to 599 million CNY in 2023 [5].

Core Viewpoint - Huahai Qingsi is a high-end semiconductor equipment supplier with core independent intellectual property, focusing on a platform strategy of "equipment + services" [1] Financial Performance - In the first three quarters of the year, the company achieved operating revenue of 2.452 billion yuan, a year-on-year increase of 33.22% [1] - The net profit attributable to the parent company was 721 million yuan, reflecting a year-on-year growth of 27.8% [1] Acquisition Details - The company plans to use no more than 1.005 billion yuan of its own funds to acquire the remaining 82% stake in its subsidiary, Xinyu Semiconductor [4] - Upon completion of the transaction, Xinyu will become a wholly-owned subsidiary of Huahai Qingsi [4] Xinyu Semiconductor's Status - Xinyu Semiconductor, established in 2018, is primarily engaged in the research, production, and sales of ion implantation machines for integrated circuits [5] - The company reported net losses of 24.42 million yuan in 2023 and 15.16 million yuan from January to May 2024 [5] Market Potential - Ion implantation machines are key equipment in the front-end process of integrated circuit manufacturing, with sales accounting for approximately 3% to 5% of the overall semiconductor equipment market [3] - The global and domestic semiconductor equipment market is highly concentrated, with over 90% of equipment supplied by American companies [5] Strategic Importance of the Acquisition - The acquisition will allow Huahai Qingsi to quickly absorb and transform core technologies related to ion implantation, facilitating rapid product and business segment development [3] - The overall price for acquiring 100% of Xinyu's equity is set at 1.225 billion yuan, with a significant appreciation rate of 1541.43% compared to the book value of Xinyu's equity [6]